Pharmacotherapy is the mainstay of IBD treatment, and can be classified into two groups of therapies: biologic—such as Anti-tumor necrosis factor (anti-TNF) agents (e.g., infliximab (INF) and adalimumab (ADA)); anti-interleukin (IL)-12 and IL-23 (e.g., ustekinumab); and anti-integrin (e.g., vedolizumab) [15,16]—and non-biologic (e.g., mesalamine, sulfasalazine, prednisolone, methylprednisolone, 6-mercaptopurine, azathioprine, methotrexate, etc.)[17]. The gene discussed is TNF; the disease is inflammatory bowel disease.